HOSPITAL COSTS ASSOCIATED WITH DEDICATED VASCULAR ENDOPROSTHESIS VERSUS PROSTHETIC BYPASS IN POPLITEAL ARTERY ANEURYSM TREATMENT IN FRANCE
Author(s)
de Léotoing L1, Jouaneton B1, Fernandes J2, Vainchtock A3, Hanoka S4
1HEVA, LYON, France, 2Oc-Santé, Montpellier, France, 3HEVA, Lyon, France, 4W.L. Gore & Associates, Paris, France
OBJECTIVES: To assess hospital costs of patients with popliteal artery aneurysm (PAA) treated by dedicated vascular endoprosthesis versus prosthetic bypass. METHODS: All hospital stays with PAA treated by endoprosthesis and prosthetic bypass were extracted from the French medical information system (Programme de Médicalisation des Systèmes d’Information, PMSI) 2013 database: implant code was used for endoprosthesis and the combination of both procedure and implant codes for prosthetic bypass. Patients were followed during one year from their first stay (March 2013/March 2014). An algorithm and a medical review excluded rehospitalisations not related to follow up for either treatment. To control confounding factors, patients from both arms were matched according to their age, gender, hospital status (public/private) and principal diagnosis ICD-10 (International Classification of Diseases) code. Associated costs during this period were added up both for the initial surgery and the related rehospitalisations: the mean 1-year cost per patient was estimated and compared between both arms. Valuation was performed considering French official tariffs. RESULTS: In 2013, 573 patients with endoprosthesis and 3,976 patients with prosthetic bypass were identified: 456 patients in each arm could be matched. Patients were 72±± €± € CONCLUSIONS: Using endoprosthesis instead of prosthetic bypass for the treatment of PAA led to a lower mean 1-year cost per patient.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PMD44
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders